VANCOUVER, Washington, March 05, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that it has closed on a financing of $17.5 million in gross proceeds, with Paulson Investment Company acting as placement agent.

The demand from both new and current investors highlights confidence in CytoDyn's clinical progress and its versatile development strategy in immuno-oncology, exploring a number of potential roles for leronlimab, the Company's first-in-class humanized monoclonal antibody that targets the CCR5 receptor.

"The successful completion of this financing in a challenging capital markets environment reflects meaningful investor support for our clinical strategy," said Robert E. Hoffman, CFO of CytoDyn. "The financing strengthens our balance sheet and is expected to fund current operations into 2027, supporting continued advancement of our clinical programs and strategic priorities. We appreciate the support of ...